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Mild cognitive impairmentThe early diagnostic value of glucose hypometabolism and atrophy as potential neuroimaging biomarkers ofmild
cognitive impairment (MCI) and Alzheimer's disease (AD) have been extensively explored using [18F]
ﬂuorodeoxyglucose positron emission tomography (FDG-PET) and structural magnetic resonance imaging
(MRI). The vast majority of previous imaging studies neglected the effects of single factors, such as age, symptom
severity or time to conversion inMCI thus limiting generalisability of results across studies. Here, we investigated
the impact of these factors on metabolic and structural differences. FDG-PET and MRI data from AD patients
(n = 80), MCI converters (n = 65) and MCI non-converters (n = 64) were compared to data of healthy sub-
jects (n = 79). All patient groups were split into subgroups by age, time to conversion (for MCI), or symptom
severity and compared to the control group. ADpatients showed a strongly age-dependent pattern, with younger
patients showing signiﬁcantly more extensive reductions in gray matter volume and glucose utilisation. In the
MCI converter group, the amount of glucose utilisation reduction was linked to the time to conversion but not
to atrophy. Our ﬁndings indicate that FDG-PET might be more closely linked to future cognitive decline whilst
MRI being more closely related to the current cognitive state reﬂects potentially irreversible damage.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Neuroimaging research in the ﬁeld of dementia focuses on the im-
pact of behavioral, neuropsychological, genetic and demographic factors
on brain atrophy associated with transition from healthy aging through
mild cognitive impairment (MCI) and further to Alzheimer's disease
(AD) (Buckner, 2004; Ewers et al., 2011; Fonteijn et al., 2012; Förster
et al., 2012; Gao et al., 1998; Gomar et al., 2011; Good et al., 2001;
Jedynak et al., 2012; Johnson et al., 2009; Tisserand et al., 2004).
We face a steadily increasing number of structural magnetic resonance
imaging (sMRI, (Davatzikos et al., 2008b; Kloppel et al., 2008)) and
[18F]ﬂuorodeoxyglucose positron emission tomography (FDG-PET,
(Habeck et al., 2008; Haense et al., 2009; Sadeghi et al., 2008)) studies
showing high sensitivity to the disease process when used separatelye terms of the Creative Com-
, which permits non-commercial
d the original author and source
anne, LREN, Département des
nne, Switzerland. Tel.: +41 21
kart).
lished by Elsevier Inc. All rights reser(Alexander et al., 2002; Anchisi et al., 2005; Jack et al., 2010; Jagust
et al., 2007; Kinkingnehun et al., 2008; Kloppel et al., 2008; Schroeter
et al., 2009) and a gain in diagnostic accuracy when used together in a
multimodal approach (Dukart et al., 2011a; Fan et al., 2008).
A viable way of understanding pathophysiology and further improv-
ing diagnostic accuracy in MCI and AD is the integration of previous
knowledge about characteristic features of progression from a healthy
state to AD. However, the straightforward interpretation of such an
integrative approach could be limited by either systematic differences
in demographic and cognitive abilities within patients and healthy con-
trols or the use of particular image data processing algorithms (Crivello
et al., 2002; Dukart et al., 2010; Jones et al., 2005). One such demo-
graphic factor that has been shown to have a strong differential impact
on disease progression is age. Previous studies have indicated that
early-onset (age b 65 years) and late-onset (age ≥ 65 years) AD pa-
tients show a differential pathology in MRI and FDG-PET (Canu et al.,
2012; Frisoni et al., 2007; Ishii et al., 2005; Kaiser et al., 2012; Karas
et al., 2007; Möller et al., 2013; Sakamoto et al., 2002). Nonetheless,
the interpretation of these differences is still controversial as the differ-
encesmight be explained by a differential age speciﬁc baseline resulting
from comparison of early- and late-onset AD patients to different age-
matched control group or to each other, by differential underlyingved.
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changes. Also the link between FDG-PET andMRI and the current (as in-
dicated by symptom severity) and future cognitive state (as indicated
by future cognitive decline) is a matter of debate. Both imaging modal-
ities have been reported to correlate with both current symptom sever-
ity and the future cognitive decline (Chételat et al., 2005; Drzezga et al.,
2003; Edison et al., 2007; Fox et al., 1999; Vemuri et al., 2009a, b). These
ﬁndings on the other side are not fully compatible with the currently
widely accepted model of progression of both imaging markers in AD
suggesting a differential time-line of progression with FDG-PET show-
ing ﬁrst a rapid decline and atrophy developing rather later in the pro-
gression from healthy aging toMCI and further to AD (Jack et al., 2010).
An accurate estimation of the unique impact of these speciﬁc factors
and their interaction on the progression of MCI or AD is crucial to
integrate ﬁndings across different studies. Longitudinal studies offer a
potential solution; although they are logistically difﬁcult to carry out
and lack complete control for all possible confounds within a cohort
(Davatzikos et al., 2008a; Drzezga et al., 2003; Johnson et al., 2009).
The aim of this study is to disentangle the effect of age, symptom se-
verity as measured by Mini Mental State Examination (MMSE, (Folstein
et al., 1975)) and time to conversion (TTC) on changes in two prominent
imaging biomarkers of AD—glucose metabolism and brain atrophy
pattern. Therefore, we systematically investigate the effect of the factors
age, symptom severity and TTC (in MCI patients) on brain pathology
observed in both imaging modalities using the same group of control
subjects whilst accounting for the effect of healthy aging using a recently
proposed approach (Dukart et al., 2011b). The use of the same group of
patients for investigation of the effects of different variables of interest
is expected to reduce potential confounding effects in other uncontrolled
factors. By additionally accounting for the variance explained by healthy
aging we target the question on how much AD related pathology is re-
quired at different ages to induce the same level of cognitive impairment.
Given the fact that age interacts with AD-speciﬁc atrophy patterns
(Franke et al., 2010; Good et al., 2001), we expected that younger MCI
converters (cMCI) and younger AD patients would show a more exten-
sive pattern of atrophy and glucose hypometabolism than older patients
with similar symptom severity. According to a recent model of MCI
progression characterised by rapid reduction in glucose metabolism
followed by brain atrophy in much later stages of disease progression
(Jack et al., 2010), we hypothesized that cMCI would initially show a
more extensive decrease in glucose utilisation compared to the amount
of atrophy associated with closeness to conversion. Keeping in mind
that both FDG-PET and sMRI correlate with cognitive decline (Fox et al.,
1999;Herholz et al., 2011),wehypothesized that by accounting for partial
volume effects (PVE) in FDG-PET, changes in symptom severity would
be more strongly linked to gray matter (GM) volume reductions than to
glucose hypometabolism during progression fromMCI to AD.
2. Methods
2.1. Subjects
To evaluate the effect of age, symptom severity and TTC on differ-
ences in FDG-PET and sMRI, we used multicenter sMRI and FDG-PETTable 1
Subject group characteristic.
Controls AD
Number 79 80
Male/Female 41/38 40/40
Age (years) 75.8 ± 4.9 75.7 ± 7.0
Age range (min–max) 62–87 55–88
MMSE (score) 28.7 ± 1.6 23.6 ± 2.2
Mean ± standard deviation. AD Alzheimer’s disease, ANOVA analysis of variance, con convert
converters.data of AD patients (n = 80), cMCI (n = 65), MCI non-converters
(ncMCI, n = 64) and healthy control subjects (n = 79) (Table 1).
The mean follow-up ± standard deviation for ncMCI was 26.8 ±
9.1 month, for cMCI 28.1 ± 8.0 month, for AD 19.8 ± 7.7 month
and for the control group 30.5 ± 8.3 month. All data were extracted
from the Alzheimer's disease Neuroimaging Initiative (ADNI) database
(www.adni-info.org). Data were selected for availability of FDG-PET
(50% of the ADNI cohort). Additionally, selection criteria were, if possi-
ble, matching for age and gender. Exclusion criteria for the current
study were reported quality problems in imaging acquisition (e.g. mod-
erate to severe motion artifacts). The cMCI group consisted of patients
who converted to AD within 36 months of follow-up. Diagnosis of AD
patients was based on NINCDS/ARDRA criteria (McKhann et al., 1984).
Only stable MCI according to all available follow-up information were
included in the ncMCI group. Similarly, group deﬁnition for all other
groups comprised all available follow-up information, e.g. only subjects
without reported conversion to MCI or AD in the available follow-up
were included in the control group. Exclusion criteria for the ADNI
data were the presence of any signiﬁcant neurological disease other
than AD, history of head trauma followed by persistent neurological
deﬁcits or structural brain abnormalities, psychotic features, agitation
or behavioral problems within the previous three months or history of
alcohol or substance abuse. A detailed description of the ADNI inclusion
and exclusion criteria can be found under the following url: http://
www.adni-info.org/pdfs/adni_protocol_9_19_08.pdf. Additionally, a list
of subjects included in our study is provided in Supplement 1. For each
subject, only data from the ﬁrst study time-point were used for further
analysis. The study was conducted according to the Declaration of
Helsinki. Written informed consent was obtained from all participants
before protocol-speciﬁc procedures were performed.2.2. MRI data
The MRI dataset included standard T1-weighted images obtained
with different 1.5 T scanner types using a 3D MP-RAGE sequence
varying in TR and TE with an in-plane resolution of 1.25 × 1.25 mm
and 1.2 mm slice thickness. All images were preprocessed as described
on the ADNI website (http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.
shtml) including distortion and B1 non-uniformity corrections.2.3. FDG-PET data
FDG-PET scanning at different PET-scanner types was performed
using one of the following three protocols: 1) dynamic: a 30 min six
frame acquisition (6 ﬁve-minute frames), with scanning from 30 to
60 min post FDG injection; 2) static: a single-frame, 30 min acquisition
with scanning 30–60 min post injection; and 3) quantitative: a 60 min
dynamic protocol consisting of 33 frames, with scanning beginning at
injection and continuing for 60 min. Images also differed in resolution,
orientation, voxel and image dimensions and count statistics. The
mean images of realigned frames from 30 to 60 min post injection
were used for further analysis.MCI con MCI noncon ANOVA (df,F,P)
65 64 –
41/24 38/26 –
75.1 ± 6.9 75.6 ± 6.8 3,0.1,.938
58–88 60–87 –
26.8 ± 1.8 27.5 ± 1.7 3,109.9,b.001
ers, MCI mild cognitive impairment, MMSE Mini Mental State Examination, noncon non-
Table 2
Subgroup characteristics for AD patients.
Age evaluation
Young AD Mean AD Old AD ANOVA (df,F,p)
Number 25 25 25 –
Male/Female 12/13 12/13 14/11 –
Age (years) 69.2 ± 3.7 75.6 ± 1.3 82.2 ± 3.0 2,131.6,b.001
Age range (min–max) 59–73 73–78 78–87 –
MMSE (score) 23.8 ± 2.1 23.8 ± 2.1 23.5 ± 2.3 2,0.2,.833
Symptom severity evaluation
High MMSE Mean MMSE Low MMSE ANOVA (df,F,p)
Number 25 25 25 –
Male/Female 11/14 14/11 12/13 –
Age (years) 75.4 ± 6.2 75.5 ± 5.8 76.5 ± 7.0 2,0.2,0.791
MMSE (score) 26.0 ± 0.7 23.9 ± 0.9 21.0 ± 0.7 2,257.9,b.001
Mean ± standard deviation. AD Alzheimer’s disease, ANOVA analysis of variance,
MCI mild cognitive impairment, MMSE Mini Mental State Examination.
Table 3
Subgroup characteristics for MCI converters.
Age evaluation
Young MCI Mean MCI Old MCI ANOVA (df,F,p)
Number 21 21 21 –
Male/Female 11/10 14/7 14/7 –
Age (years) 67.9 ± 4.1 75.6 ± 1.8 82.0 ± 2.9 2,109.2,b.001
Age range (min–max) 58–72 73–78 79–88 –
MMSE (score) 27.3 ± 1.9 26.9 ± 1.6 26.1 ± 1.7 2,2.8,.068
TTC (months) 21.1 ± 7.7 19.4 ± 9.8 18.0 ± 7.8 2,0.7,.493
Symptom severity evaluation
High MMSE Mean MMSE Low MMSE ANOVA (df,F,p)
Number 21 21 21 –
Male/Female 14/7 15/6 11/10 –
Age (years) 72.6 ± 6.8 76.3 ± 5.0 76.5 ± 7.5 2,2.4,.1
MMSE (score) 28.8 ± 0.7 26.9 ± 0.6 24.8 ± 0.6 2,218.6,b.001
TTC (months) 21.4 ± 8.6 20.3 ± 8.2 16.9 ± 8.4 2,1.7,.193
Time to conversion evaluation
24 months 18 months 12 months ANOVA (df,F,p)
Number 15 15 15 –
Male/Female 10/5 9/6 8/7 –
Age (years) 76.3 ± 5.1 76.8 ± 7.7 76.8 ± 5.9 2,0.0,.973
MMSE (score) 27.1 ± 1.7 26.7 ± 1.8 26.5 ± 1.8 2,0.4,.701
Mean ± standard deviation. ANOVA analysis of variance, MCI mild cognitive impairment,
MMSE Mini Mental State Examination.
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All image-processing stepswere carried out using the SPM5 software
package (Wellcome Trust Centre for Neuroimaging: http://www.ﬁl.ion.
ucl.ac.uk/spm/) implemented in Matlab 7.7 (MathWorks Inc., Sherborn,
MA). For common pre-processing sMRI and FDG-PET data we applied
the same preprocessing procedure as described in detail in Dukart et al.
(Dukart et al., 2011a). In this procedure, structural MRI data were ﬁrst
interpolated to an isotropic resolution of 1 × 1 × 1 mm3, bias corrected
for inhomogeneity artifacts and segmented into greymatter, white mat-
ter and cerebrospinal ﬂuid (only the grey matter segments were used
for further analyses). The segmented grey matter images were spatially
normalized to a study speciﬁc template created from all subjects using
a diffeomorphic registration algorithm—DARTEL (Ashburner, 2007).
In this step, the images were modulated using Jacobian determinants
to preserve the total amount of signal from each region. The obtained
grey matter volume images were smoothed with a Gaussian kernel
of 12 mm full width at half maximum and masked using a grey matter
mask created by thresholding the ﬁrst and the last DARTEL template by
0.2 to avoid big edge effects.
2.5. FDG-PET pre-processing
FDG-PET data were interpolated to an isotropic resolution of
1 × 1 × 1 mm3 and co-registered to the corresponding sMRI scan
of each subject using the co-registration function in SPM5. Further
pre-processing included a convolution based PVE correction (Muller-
Gartner et al., 1992; Quarantelli et al., 2004) of FDG-PET using sMRI
data and subsequent masking of non-GM voxels. Spatial normalisation
to a study speciﬁc template was performed using ﬂow-ﬁelds obtained
from sMRI data (Ashburner, 2007). As for sMRI a smoothing kernel of
12 mm full width at half maximum was applied to all FDG-PET data.
The obtained FDG-PET and grey matter volume images had a very sim-
ilar effective smoothness as indicated by subsequent SPM smoothness
estimation during statistical analyses. FDG-PET data were intensity
normalized to the cerebellar mean glucose uptake and masked using a
grey matter mask to avoid big edge effects. The cerebellar region was
chosen for intensity normalisation of FDG-PET as it has been shown to
be a region of choice for intensity normalisation which is unaffected in
healthy ageing and early stages of AD when correcting for PVE caused
by atrophy (Dukart et al., 2010; Kushner et al., 1987).
2.6. Correction for age effects
To remove the effect of healthy aging on glucose utilisation and
regional grey matter volumes we ﬁrst computed voxel-wise linear
regressions only in control subjects and separately for both imaging
modalities. In a second step the beta coefﬁcients obtained from
the voxel-wise linear regressions are applied to remove the vari-
ance explained by healthy ageing in patients' and control subjects'
imaging data (Dukart et al., 2011b).
2.7. Statistical analysis of imaging data
All statistical analyses of imaging data were carried out within
the SPM5 framework. To investigate the effect of age on differences ob-
served in FDG-PET andMRI inMCI andAD, the entire groups of AD, cMCI
or ncMCI subjects were split based on age, symptom severity (MMSE
score) or TTC (only for MCI converters) into 3 equally sized subgroups
(Tables 2, 3, 4) matching for the remaining one (or two for cMCI) vari-
ables. For example for the subdivision of the AD group by age the
80 AD subjects were sorted in an ascending order by age and then
divided into three equally sized biggest possible subgroups (for AD 26
subjects per group: 26 ∗ 3 = 78) and leaving the remaining subjects
for potential matching. Analyses of variance and if signiﬁcant subse-
quent post-hoc t-tests were then computed to evaluate the subgroupsfor potential differences in variables of no-interest for the particular
comparison (e.g. for age: MMSE (for cMCI also for TTC) and vice
versa). If one of the tests indicated signiﬁcant differences between
the subgroups (e.g. signiﬁcantly lower MMSE scores in younger AD),
subjects with the extreme values in the corresponding group (in this
case low MMSE scores) were replaced by some of the subjects left for
matching and showing similar age values but higher MMSE scores.
The statistical tests were then recomputed. If a test again revealed
signiﬁcant differences the subgroup size was reduced by removing
from each subgroup one subject showing “extreme” relative values as
compared to the mean of the subgroup in the signiﬁcant variable of no
interest. This procedure of replacing subjects or removing one subject
from each subgroup was then repeated until matching in variables of
no interest was achieved for each group and each subgroup splitting.
FDG-PET and voxel-based morphometry (VBM) data of each subgroup
were compared separately with the entire group of control subjects.
Additionally, subgroupswerematched for gender. Therewere no signif-
icant differences in the distribution of the FDG-PET protocols between
the obtained subgroups.
Table 4
Subgroup characteristics for MCI non-converters.
Age evaluation
Young MCI Mean MCI Old MCI ANOVA (df,F,p)
Number 21 21 21 –
Male/Female 11/10 13/8 13/8 –
Age (years) 68.0 ± 4.6 75.7 ± 1.8 82.6 ± 2.4 2,111.2,. b .001
Age range (min–max) 60–74 74–79 79–87 –
MMSE (score) 27.7 ± 1.4 28.1 ± 1.5 26.9 ± 1.8 2,3.1,.051
Symptom severity evaluation
High MMSE Mean MMSE Low MMSE ANOVA (df,F,p)
Number 21 21 21 –
Male/Female 13/8 12/9 12/9 –
Age (years) 75.1 ± 6.2 75.4 ± 6.8 75.7 ± 7.3 2,0.0,.957
MMSE (score) 29.2 ± 0.5 27.7 ± 0.5 25.6 ± 1.8 2,105.4,b.001
Mean ± standard deviation. ANOVA analysis of variance, MCI mild cognitive impairment,
MMSE Mini Mental State Examination.
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healthy controls were performed using a full factorial analysis of vari-
ance (ANOVA) design controlling for gender and total intracranial vol-
ume (for VBM). Total intracranial volume was calculated by counting
all voxels in a sum image of greymatter, whitematter and cerebrospinal
ﬂuid probability maps of each subject exceeding an absolute threshold
of 0.2. This volume measurement was then recomputed into litres. In
this, the three clinical subgroups (depending on split for age, symptom
severity or TTC [only for cMCI]) and the control group were entered
as independent factors. T-contrasts were used to evaluate differences
between subgroups and control subjects. In contrast to classical para-
metric analyses, subgroup comparisons also provide the possibility
to detect more complex relationships between age, symptom severity
and TTC and differences observed in both imaging modalities. Such a
complex relationship would be for example an increase in glucose
hypometabolism only in middle-aged but not in younger or older AD
patients. This kind of u-shaped relationships would not be detected by
a regression analysis. A signiﬁcance threshold of p b 0.001 uncorrected
at voxel-level and p b 0.05 FWE-corrected for multiple comparisons at
cluster level accounting for non-stationary smoothness in imaging
data (as suggested for voxel-based morphometry data, Worsley et al.,
1999; Hayasaka et al., 2004) was used for all imaging contrasts. This
approach has been explicitly suggested for VBM analyses. It is based
on the random ﬁeld theory and is determining for any chosen voxel-
based statistical threshold a corresponding cluster extent threshold
which each cluster has to exceed taking into account i) the voxel-wise
statistical threshold, ii) the smoothness of the data and iii) the total
amount of comparisons.
As in our studywe further aimed to investigate differences in the ex-
tent of atrophy and glucose hypometabolism related to age, symptom
severity and TTC in the subgroups, the extents of detected differences
within each modality between different conditions and between the
modalities for each condition were compared to each other using two
proportions z-tests. Thereby the total amount of detected signiﬁcant
voxels for each comparison was expressed as a proportion relative to
the total amount of voxelswithin the statisticalmask. Further, as thedif-
ference in proportions of signiﬁcant voxels is highly dependent on the
chosen signiﬁcance threshold (e.g. at a high threshold the same differ-
ence in cluster extent is less likely than at a lower threshold) and on
data smoothness, the sample size was calculated as the total amount
of tested voxels scaled by a factor calculated as the number of expected
clusters times number of expected voxels per cluster. This information
about number and extent of expected clusters is provided within the
SPM software in the statistical evaluation of each contrast and is based
on estimates of data smoothness and the chosen statistical threshold.
For these comparisons a statistical threshold of p b .05 Bonferronicorrected for the total amount of comparisons within each group was
chosen.
2.8. Parametric analyses
To additionally evaluate parametric differences related to age, symp-
tom severity and TTC in FDG-PET and sMRI we performed three regres-
sion analyses for each of the modalities using either only AD, cMCI or
ncMCI subjects. Age, gender and MMSE were included in all regression
analyses with additional inclusion of TTC for the cMCI group. For
all sMRI regression analyses total intracranial volume was included in
the design matrix. Correlations of imaging data with age and MMSE
were evaluated for all clinical groups. In addition, correlations with
TTC were calculated for cMCI.
A signiﬁcance threshold of p b 0.001 uncorrected at voxel-level and
p b 0.05 FWE-corrected for non-stationarity of smoothness at cluster
level was used (Hayasaka et al., 2004).
2.9. Statistical analysis of behavioral data
We performed ANOVAs for group comparisons for age andMMSE in
the entire dataset and for all subgroups (Tables 1, 2, 3). cMCI subgroups
were additionally compared to each other for TTC. If an ANOVA revealed
a signiﬁcant between-group effect, a Bonferroni t-test was calculated
with a signiﬁcance threshold of p b .05 (corrected for multiple compar-
isons, two-tailed). Group differences regarding sex were evaluated
using a chi-square test for independent samples. The statistical analyses
were performed with the commercial software package SPSS 17.0
(http://www.spss.com/statistics/). Additionally, we calculated correla-
tions between all variables of interest for each clinical group separately
with a signiﬁcance threshold of p b .05 (Bonferroni corrected formultiple
comparisons, where deemed appropriate).
3. Results
3.1. Imaging results
3.1.1. Age
In young AD patients relative GM volume loss affected almost the
whole cortex, sparing only sensorimotor and occipital regions (Fig. 1).
In subcortical areas, both thalami were also atrophic. In middle-aged AD
patients GM atrophy extended bilaterally to hippocampus, thalamus, cer-
ebellum, cingulate, precuneate, parietal, temporal, occipital, frontal and
insular cortices and to right putamen. In older AD patients we observed
atrophy in bilateral hippocampi, thalami, temporal, temporo-parietal,
sensorimotor and right occipital regions. In young AD patients glucose
hypometabolism was observed in bilateral temporo-parietal, precuneus,
posterior cingulate, lateral frontal, medial frontal and posterior thalamic
regions. Glucose hypometabolism in middle-aged AD patients was
restricted to bilateral temporo-parietal, right frontal, bilateral posterior
cingulate regions and precuneus and in older patients to bilateral pre-
cuneus and to the right parietal cortex.
Young cMCI showed atrophy in bilateral hippocampal, precuneate,
posterior cingulate, left parietal and right temporal cortices (Fig. 1).
Middle-aged cMCI showed a very similar but more widespread pattern
of atrophy additionally involving the right insula and both anterior
thalami. In older cMCI, the most widespread atrophy was found that
involved bilateral parietal, temporal and frontal cortices, the thalamus
and the hippocampus. In contrast, glucose utilisation was most strongly
reduced in young MCI converters, involving medial and lateral frontal,
temporal, parietal and insular cortices, the cingulum, basal ganglia,
thalamus and hippocampus. Both middle-aged and old cMCI showed
glucose hypometabolism in precuneate and temporo-parietal regions.
Additionally, older cMCI had reduced glucose metabolism in medial
and lateral frontal cortical regions.
Fig. 1.MRI and FDG-PET results for the comparison of three groups of AD patients,MCI converters (cMCI) and non-converters (ncMCI) split by age compared to the same group of control
subjects. a) MRI (blue: atrophy) and FDG-PET (red: hypometabolism) results plotted onto an averaged brain. Overlapping results are displayed in violet. Results for differently aged sub-
groups are separated by rows. Results for different clinical groups are separated by columns. Cortical hypometabolism in ncMCI patientswas restricted to the right hemisphere. In contrast,
in both other groups the results were much more symmetric however with more extensive changes in the left hemisphere. b) Number of signiﬁcant voxels (p = 0.001 uncorrected
at voxel level and p = 0.05 FWE corrected at cluster level) detected in each comparison in FDG-PET (red) andMRI (blue). AD Alzheimer’s disease, FDG-PET [18F]ﬂuorodeoxyglucose positron
emission tomography, FWE family-wise error, MCI Mild Cognitive Impairment, MRI structural magnetic resonance imaging, * indicates a signiﬁcant difference between modalities within the
condition, ** indicates a signiﬁcant difference to all other conditions within the modality. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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utilisation was reduced in younger ncMCI in precuneate, temporal,
parietal, lateral and medial frontal, hippocampal and thalamic regions.
Middle-aged ncMCI showed decreased glucose metabolism in the right
polar frontal cortex. No hypometabolism was observed in older ncMCI.
3.1.2. Symptom severity
In mild AD, atrophy was mainly restricted to precuneus, posterior
cingulate, hippocampal, anterior thalamic, insular, lateral frontal, tem-
poral and parietal regions. In contrast, in the moderately impaired AD
group, atrophy was more extensive in parietal and temporal cortices
and additionally involved orbito-frontal regions. In the more severe
AD group, atrophy involved almost all cortical and subcortical struc-
tures, sparing only some motor regions and most parts of the cere-
bellum. AD patients with mild symptom severity showed decreased
glucose utilisation in precuneus, bilateral temporal and right parietal
regions. In moderately and severely impaired AD patients, we detected
impaired glucose utilisation in a bilateral network consisting of lateral
frontal, temporo-parietal and precuneate regions.
In both mild and moderate cMCI, atrophy was restricted to bilateral
hippocampal and right temporal regions. cMCI with lowest MMSE
scores revealed a more wide-spread pattern of atrophy covering lateral
and orbital frontal, parietal, temporal, insular and occipital cortices
in the patient group. Further, in this group, atrophy was signiﬁcant
in precuneate, hippocampal and anterior thalamic regions. In all threegroups of cMCI glucose hypometabolism extended to temporo-parietal,
lateral and medial frontal regions and precuneus. Additionally, cMCI
with moderate symptom severity showed reduced glucose metabolism
in both thalami and right caudate nuclei. Further, in cMCI with com-
parablymild symptom severity, we observed reduced glucose utilisation
in orbito-frontal and insular cortices.
In ncMCI, only the group with the lowest MMSE showed signiﬁcant
atrophy in the right hippocampus whilst glucose hypometabolism was
restricted to right precuneus and parietal regions (Fig. 2).
3.1.3. Time to conversion (TTC)
In the cMCI group converting to AD 24 months after initial presenta-
tion, GM atrophy was observed in hippocampal, anterior thalamic
and right temporal regions (Fig. 3). In cMCI with a TTC of 18 months,
GM atrophy was only detected in bilateral hippocampus. In the cMCI
group converting to AD in12 months, atrophywas restricted to bilateral
hippocampus and to right temporo-parietal and temporal cortices.
In cMCI with a TTC of 24 months glucose utilisation reductions
were restricted to right temporo-parietal, right temporal and bilateral
precuneate regions. In the cMCI group converting to AD 18 months
glucose hypometabolism was found in temporal, cingulate, lateral and
medial frontal and parietal regions. Glucose utilisation reduction was
even more prominent in the group converting to AD in 12 months,
involving precuneate, parietal, temporal, lateral and medial frontal,
cingulate and insular regions.
89J. Dukart et al. / NeuroImage: Clinical 3 (2013) 84–943.2. Parametric resultsFig. 2.MRI and FDG-PET results for the comparison of three groups of AD patients, MCI converters (cMCI) and non-converters (ncMCI) split by symptom severity compared to the same
group of control subjects. a) MRI (blue: atrophy) and FDG-PET (red: hypometabolism) results plotted onto an averaged brain. Overlapping results are displayed in violet. Results for
differently affected subgroups are separated by rows. Results for different clinical groups are separated by columns. b) Number of signiﬁcant voxels (p = 0.001 uncorrected at voxel
level and p = 0.05 FWE corrected at cluster level) detected in each comparison in FDG-PET (red) and MRI (blue). AD Alzheimer's disease, FDG-PET [18F]ﬂuorodeoxyglucose positron
emission tomography, FWE family-wise error, MCI Mild Cognitive Impairment, MRI structural magnetic resonance imaging, * indicates a signiﬁcant difference betweenmodalities within
the condition, ** indicates a signiﬁcant difference to all other conditionswithin themodality. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)In the AD group, we observed signiﬁcant positive correlations of
age with GM volume in bilateral occipital, parietal, temporal, frontal,
posterior cingulate and cerebellar regions (Fig. 4). Given that we
removed the voxel-wise effect of healthy aging on glucose utilisation
and regional grey matter volumes in all patients based on estimates
from healthy controls (Dukart et al., 2011b), positive correlations
with age in AD indicate that less disease-related GM atrophy or
glucose hypometabolism is required in higher age compared to
lower age to induce the same symptom severity. Further signiﬁcant
correlations were observed in right insula and right dorsal nucleus
caudatus. MMSE correlated with GM volume in bilateral parietal,
temporal, frontal regions, posterior hippocampal and thalamic regions.
In all clinical groups no further signiﬁcant sMRI correlations were
observed with any of the variables.
In AD signiﬁcant positive correlations between age and glucose
metabolism were observed in bilateral parietal and temporal cortices.
In cMCI signiﬁcant positive right-sided correlations with age were
observed in parietal and temporal regions and in putamen. In ncMCI
we observed signiﬁcant positive correlations of age with glucose
metabolism in right putamen, right parietal, temporal, premotor and
insular regions and in left anterior cingulate cortex.
3.3. Behavioral results
In comparison of all groups of AD patients, cMCI, ncMCI and control
subjects, there was no signiﬁcant difference of age or sex [χ2(3) = 3.2;
p = .348]. MMSE differed signiﬁcantly between control subjects and
patients [Controls vs. MCI converters: t(142) = 6.5;p b .001; Controlsvs. ncMCI: t(103) = 4.2;p = .001; Controls vs. AD: t(141) = 16.6;p b .001]. There was a signiﬁcant difference in MMSE between MCI
and AD patients [cMCI vs. AD: t(143) = 9.6;p b .001; ncMCI vs. AD:
t(142) = 11.8;p b .001]. The difference between cMCI and ncMCI was
not signiﬁcant [t(127) = 2.3;p = .209].
The subgroups of AD patients, cMCI and ncMCI, used for evaluation
of age effects on FDG-PET and sMRI did not differ in symptom severity
(Tables 1, 2, 3) or in relation to sex. Of course, the between-group differ-
ences in age for the three subgroup comparisons were all highly signif-
icant (p b .001). For AD, cMCI and ncMCI subgroups used for symptom
severity evaluation, age (Tables 2, 3, 4) and sex did not differ between
subgroups. As expected, MMSE scores differed signiﬁcantly (p b .001)
for these comparisons for AD, cMCI and ncMCI subgroups. Subgroups
of cMCI for evaluation of TTC-related differences in FDG-PET and sMRI
did not differ in age, sex or symptom severity.
Correlational analyses in the AD group revealed only very weak,
insigniﬁcant correlations between age and symptom severity as mea-
sured by MMSE [r = − .09;p = .444]. In the cMCI group, the variables
age, symptom severity and TTC were also only weakly but insigniﬁcantly
correlated [age andMMSE: r = − .24;p = .156; age and TTC: r = − .11;
p = 1.0; MMSE and TTC: r = − .10;p = 1.0]. Similarly, there was no
signiﬁcant correlation between age and MMSE in ncMCI [r = − .21;
p = .095].
4. Discussion
In this study we demonstrate and dissociate differential patterns
of structural and metabolic brain differences related to age, symptom
severity and disease progression in AD, cMCI and ncMCI subjects.
Fig. 3.MRI and FDG-PET results for the comparison of three subgroups of MCI converters split by time to conversion compared to the same group of control subjects. a) MRI (blue: atro-
phy) and FDG-PET (red: hypometabolism) results plotted onto an averaged brain. Overlapping results are displayed in violet. Results for different subgroups are separated by columns.
b) Number of signiﬁcant voxels (p = 0.001 uncorrected at voxel level and p = 0.05 FWE corrected at cluster level) detected in each comparison in FDG-PET (red) and MRI (blue).
AD Alzheimer's disease, FDG-PET [18F]ﬂuorodeoxyglucose positron emission tomography, FWE family-wise error, MCI Mild Cognitive Impairment, MRI structural magnetic resonance
imaging, * indicates a signiﬁcant difference between modalities within the condition, ** indicates a signiﬁcant difference to all other conditions within the modality. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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between the spatial extent of AD related imaging pathology and age,
symptom severity and TTC. This focus on spatial extents of pathology
contrasts our study from previous research targeting rather the cor-
relational link between these variables and the grade of glucose hypo-
metabolism or atrophy at each particular voxel/region. Both types of
relationships are rather independent. For example a reduction of neural
function in a particular region under a particular threshold might have
an impact on cognitive performance. However, any further increase
in AD pathology in the very same region might not have any addi-
tional effect on cognition and would be therefore not detected by
a correlational analysis. In this case only additional impairment of
other brain regions would lead to further cognitive decline. By com-
paring all patient groups to the same control group and adjusting forhealthy aging we further for the ﬁrst time account for the potential
confounding effect of the use of different control groups that was
neglected in previous research.
The cMCI and ncMCI differ in the amount of glucose hypometabolism
and brain atrophy explained by age and symptom severity with cMCI
resembling AD patients. We conﬁrm previous ﬁndings of a correlation
between TTC and glucose metabolism as well as an inverse relationship
between age increase and amount of atrophy and hypometabolism asso-
ciated with a particular symptom severity in AD (Matsunari et al., 2007;
Salmon et al., 2000). Given that we account for differences associated
with healthy aging, our ﬁndings of differences in the amount of glucose
hypometabolism and atrophy in AD subgroups subdivided by age
can be interpreted as pathological age-speciﬁc add-ons that relate
to a degree of functional impairment.
Fig. 4. Signiﬁcant age and MMSE related positive correlations observed in MRI (blue) and FDG-PET (red) in AD patients, MCI converters (cMCI) and MCI non-converters (ncMCI).
AD Alzheimer's disease, FDG-PET [18F]ﬂuorodeoxyglucose positron emission tomography, MCI Mild Cognitive Impairment, MRI structural magnetic resonance imaging. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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age-related glucose hypometabolism and atrophy patterns between
clinical groups have implications for the use of neuroimaging bio-
markers for improving diagnostic accuracy and prediction of conversion
to AD. While FDG-PET is the dominant biomarker in young cMCI and
atrophy is mainly restricted to the hippocampus, the pattern observed
in old cMCI is of prominent atrophy associated with equally marked
glucose hypometabolism. This observation is consistent with a relative
diagnostic superiority of FDG-PET compared to sMRI in younger pa-
tients with mild AD symptoms (Kawachi et al., 2006; Matsunari et al.,
2007). The age-related differential pattern of abnormality discovered
with FDG-PET and sMRI supports previous ﬁndings of better diagnostic
performancewith FDG-PET only in early-onset AD patients, but equiva-
lent performance for the two in elderly patients (Matsunari et al., 2007).
The second ﬁnding concerns the relationship between symptom
severity as measured by classical screening and the progression of
changes in FDG-PET and sMRI. We demonstrate for cMCI and AD pa-
tients a strong link between symptom severity and the amount of atro-
phy, which is not evident in ncMCI. Interestingly, no such pattern was
seen in glucose metabolism with any of the patient cohorts. This result
indicates that changes measured by sMRI are more strongly related to
the current symptom severity in AD patients.
A third, more surprising result was obtained when MCI converters
were split by TTC. We expected that symptom severity and TTC would
be strongly linked, as neuropsychological measurements are used to
determine AD stage. However, the measurements are only weakly corre-
lated, which suggests that different mechanisms produce current (as
measured by MMSE) and future cognitive states (as measured by TTC).
Thus, a comparison of TTC duration subgroups with healthy control
subjects showed a TTC-dependant amount of glucose hypometabolism,but no relationship with the amount of atrophy. The link between FDG-
PET measurements and subsequent cognitive decline is consistent with
previous reports showing the superiority of FDG-PET compared to neuro-
psychological measurements for prediction of subsequent cognitive
decline and conversion to AD in MCI patients (Arnaiz et al., 2001;
Chételat et al., 2005; Hinrichs et al., 2011).
The differential results for TTC and symptom severity-related dif-
ferences observed with FDG-PET and sMRI cannot be explained by dif-
ferent pathologies or other factors because the cMCI subgroups came
from splitting the same group of subjects.
The current view of the progression of FDG-PET and sMRI changes
in AD is that functional abnormalities occur earlier than those with
sMRI (Jack et al., 2010). Our results suggest amodiﬁcation of the current
model of biomarker changes related to progression from MCI to
AD (Jack et al., 2010). Imaging abnormalities appear at an early stage
in sMRI as well as FDG-PET; however, structural changes are restricted
mainly to the hippocampus. In contrast, but consistent with the sug-
gested model, glucose hypometabolism progresses rapidly in this
early stage of AD. The model suggested by Jack et al. further implies
that the magnitude of biomarker changes is equal in both FDG-PET
and structural MRI data (Jack et al., 2010). The assumption behind this
idea is that structural changes follow functional changes. In contrast,
our data suggest that FDG-PET changes reach their peak already at the
MCI stage (Figs. 2 and 3) and do not further increase but rather decrease
(e.g. because the preserved tissue is maintaining its functional activity
level) at later disease stages when adjusting for atrophy effects using
PVE correction. In contrast, atrophy further increases at later AD stages
in our study population and even extends to regions not showing
any signiﬁcant hypometabolism. For this reason we expect that if one
would not use PVE correction, one would observe further reductions
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Although the results of our study are relevant to improving under-
standing of progression fromMCI to AD, some limitations need consider-
ation to enable valid interpretation. Firstly, we used the same clinical
groups to examine different variables of interest, with splitting into dif-
ferent subgroups depending on expression of the variables of interest.
Therefore, the results may be confounded by between-group differences
in uncontrolled factors such as functional asymmetries, intelligence
quotient and other more speciﬁc cognitive domains associated with
Alzheimer's disease. Such differences in uncontrolled factors might
have contributed to the observed differences in the amount of atrophy
and hypometabolism and shall be overcome in future large-scale longitu-
dinal studies. Secondly, although subgroup comparisons for confounding
variables were not signiﬁcant in ANOVAs, they could have contributed to
the differential results.We feel this is unlikely to have introduced any sys-
tematic bias, as the between-group differences were small and restricted
to only one of the subgroups.
When removing the variance explained by healthy ageing in the
imaging datawemake the explicit assumption of linearity of age related
differences inGMvolume and glucosemetabolism. This issue has been a
major focus of several large scale volumetric and PET studies performed
in the past two decades (Gonoi et al., 2009; Good et al., 2001; Loessner
et al., 1995; Smith et al., 2007). All of these studies provided strong
evidence that linear as compared tomore complexmodels are sufﬁcient
to describe global and local atrophy and glucose metabolism reductions
observed in the course of normal ageing (from the age of 20 to
100 years. Our assumption is therefore in line with previous research
performed on that topic. Nonetheless, imprecisions of the applied
voxel-wise healthy ageing models e.g. due to wrong linearity assump-
tions are a general possible confounding effect for studying age-
speciﬁc differences in diseased populations. In this framework it is
also important to note that age-related ﬁndings we report in our study
only reﬂect cross-sectional differences in sMRI and FDG-PET between
differently aged AD/MCI patient groups. They should therefore not
be confused with within subject longitudinal changes related to AD
progression.
A further limitation of our study is that a proportion of control
subjects used in our study might have a preclinical AD pathology. The
inclusion of such subjects could have lowered the effects observed
in subgroup comparisons and therefore lead to an underestimation of
the amount of AD pathology. Similarly, one cannot exclude that also
some of the ncMCI would have converted to AD (or reverted from MCI
to normal range) if followed for a longer time period. As indicated in
previous studies on MCI with a follow-up of 10 years more than 80%
of MCI are expected to convert to AD in the long term (Visser et al.,
2006). Current ADNI group assignments should be therefore considered
carefully and the results need to be validated using cohorts with a lon-
ger follow-up than currently available from the ADNI. However, this
limitation is common to all imaging studies including not pathologically
proven AD patients and control subjects. Furthermore, as we compare
all subgroups exactly to the same control group, the potential inclusion
of control subjects with preclinical AD would affect all comparisons in
the same way without introducing a bias towards a speciﬁc subgroup.
Also the ﬁnding of only a very weak link between TTC and symptom
severity in our cohort requires careful interpretation. TTC is only a
crude and general estimate of cognitive function. It is therefore likely
that some more speciﬁc cognitive tests might be more closely related
to disease progression as indicated by TTC. It is important to note that
all differential results reported in our study are detected by comparing
all patient subgroups to the same control group. We therefore provide
only indirect evidence for between-subgroup differences. In contrast,
the direct subgroup comparisons were not signiﬁcant. These ﬁndings
therefore need to be validated in future studies by direct comparisons
of patient subgroups using larger data sets than currently available
from ADNI and preferably in longitudinal study designs.In our study we observed a slight decrease in sensitivity of FDG-PET
at later as compared to earlier AD stages. We interpret this effect as
an interaction of pathophysiology with the PVE correction performed
in our study. However, this effect might be also caused by methodical
artifacts, e.g. due to intensity normalisation (cerebellar metabolism is
known to decline in AD) or due to increasing inaccuracy of PVE correc-
tion caused by increasing cortical atrophy and associated problemswith
accurate MRI segmentation.
Our results have potential implications for the selection of biomarkers,
MCI staging and for treatment evaluation. While FDG-PET appears to be
amore sensitive biomarker of disease progression at theMCI stage, struc-
tural differences as measured by sMRI seem to be more strongly linked
to the current global cognitive state, potentially reﬂecting irreversible
damage. Therefore, we suggest that for treatment evaluation it may be
crucial to use both structural and functional biomarkers.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2013.07.005.
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